Medication burden in older adults is a solvable problem

An older adult arrives at a facility carrying the decisions of three prescribers, none of whom saw the whole list. Nobody set out to build an eleven-drug regimen. It assembled itself, one reasonable decision at a time.

DWARAA reads that list back as one list, for one person, and asks with the prescriber what each drug is still doing. It is a division of the Sevadar Foundation. There is nothing to buy.

Never stop or change a prescribed medication without your prescriber. Several classes rebound or cause withdrawal when stopped abruptly. Some must come down over weeks or months under supervision. The ask is a conversation, not a decision made alone.

Tap the directory assistant, the light in the corner of the page, if you need a different starting point.

What does dwaraa mean?

ਦੁਆਰਾ is Gurmukhi. It means "through," "by way of" or "via," and reads as a passage or gateway. The mark is a house roof drawn over a heart. In prose the program is an acronym, DWARAA, because each letter is a step. The wordmark is lowercase.

What is deprescribing?

The structured review of what a person takes, why each drug was started, and whether that reason still holds. Done with the person, never to them.

It does not mean zero. Every drug earns its place or gets reconsidered. Nobody is left in withdrawal or untreated pain because a number on a chart looked wrong to someone who never met them.

Two facts hold at once:

1. Older adults take more medication than the evidence supports. A drug started in the hospital for a passing problem becomes permanent. A side effect gets treated as a new disease.
2. Undertreatment is real too. The fix for overprescribing gets applied as a blunt instrument: a target, a policy, a percentage. Someone whose pain is controlled and whose function is good gains nothing from having that reversed to hit a metric.

Deprescribing done to a person is not stewardship. It is a different failure with better paperwork.

Why is my parent on so many medications?

Nobody decided on nine. The list builds from five sources:

• A hospital drug that never stopped. The classic case is a stomach-acid drug started to prevent a stress ulcer in intensive care. In one study of nine ICUs, 60% of new prescriptions had no long-term reason and 27% of those patients went home still taking them.
• A side effect treated as a new problem. Drug one causes dizziness. Drug two treats the dizziness. Drug two causes its own problem. This is a prescribing cascade, visible only when the list is read in the order it was written.
• A condition that resolved while its treatment continued.
• Three prescribers, hospital, family doctor and specialist, each making a good decision without seeing the other two.
• Preventive drugs kept past the point they could help. A drug that takes five years to pay off does little for someone with a two-year outlook.

The structural cause is simple. Adding a medication has an owner. Removing one does not. A careful review takes time nobody bills for, so at scale it does not happen.

What are the six DWARAA steps?

Each step is the precondition for the next. Skip one and the failure moves somewhere less visible.

D: Deprescribing for health optimization. The review of each drug and its reason. First, because a sedated person cannot be assessed, engaged or rehabilitated.

W: Well-being and cognitive enhancement. What replaces a reduced drug. A shorter list with nothing behind it is not deprescribing. It is withdrawal. Plan the substitute before the reduction.

A: Assessment of individual care needs. The baseline that makes every later judgment legitimate. A drug that is dead weight for one resident is load-bearing for another. You cannot detect a change in someone you never measured.

R: Reducing medication burden. Burden is not count. "Five or more" is a research convention, not a clinical threshold. Anticholinergic and sedative load tracks physical function far better than the number of lines on the list.

A: Advocating for non-pharmacological interventions. The first line, not the fallback. A behavior that stops when someone is taken to the bathroom was never a psychiatric symptom.

A: Adjusting care plans on ongoing evaluation. The step that proves the other five were real. A plan written on admission describes a person who no longer exists a year later.

DWARAA is not a protocol. No taper schedule, no drug list, no count that triggers action. Those are clinical decisions about individuals. The framework standardizes the question, asked in the same order, by everyone, about the same list.

Which medications most often need review?

Nine classes cover most of it:

• Opioids. Real pain, real risk, and a tapering literature widely misread.
• Benzodiazepines. The clearest harm signal in older adults and the best-tested way off.
• Z-drugs. Sold as the safer alternative. Largely the same receptor, largely the same risks.
• Antipsychotics. A boxed warning, a mortality signal in dementia, and cases where they are still right.
• Anticholinergics. A burden that belongs to the whole list, not one line.
• Proton pump inhibitors. In 22 Midwestern skilled nursing facilities, 79.7% of Medicare Part A admissions were on one and 65.3% of those had no appropriate diagnosis. A drug treating nothing carries only risk.
• Statins in the very old. Time to benefit, the diabetes trade-off, and the age group the trials underenrolled.
• Antihypertensives. The pathway from an over-tight dose to a broken hip.
• Gabapentinoids. Prescribing that grew as opioid prescribing fell, in a population that clears them slowly.

Age changes the margin. The same dose does more. The same fall does more damage. The same sedation gets read as decline instead of a side effect.

Why is deprescribing opioid stewardship?

Opioids, benzodiazepines, Z-drugs and antipsychotics sit at the center of stewardship everywhere in medicine. DWARAA applies the same rule in old age: each drug is earning its place or being reconsidered, with the person. The broader practice position is on opioid stewardship.

With opioids, both errors kill. Untreated severe pain is not a safe alternative to opioid therapy. Neither is a taper imposed on someone who did not agree to it.

That is the regulator's position. The CDC's 2022 guideline states that opioid therapy should not be discontinued abruptly, and doses should not be rapidly reduced from higher levels, unless there is a life-threatening issue such as warning signs of overdose. It states that policies drawn from its 2016 guideline, including rapid tapers, rigid dose thresholds and patient dismissal, contributed to untreated pain, serious withdrawal, overdose and suicidal ideation. And it names the two conditions under which lower doses improve function and mood: the reduction is slow, and it is voluntary.

The data agree. Among 113,618 US adults on stable long-term opioid therapy, tapering was associated with higher overdose and mental health crisis rates, and faster tapers carried more risk. How the practice approaches adults on high doses: opioid tapering.

Do sedating medications cause falls?

Yes. Not in doubt.

Sedating medications impair gait, balance and reaction time, and their labels say so. That is a regulatory finding, not just an association. The AGS Beers Criteria advise avoiding benzodiazepines and Z-drugs in older adults specifically because of falls and fractures.

Benzodiazepine users carry about a one-third higher hip fracture risk. Z-drugs are no safer. Risk spikes at the moment of change: fall risk was about 3.8 times higher in the 24 hours after a benzodiazepine was started, in long-stay nursing home residents with a mean age of 87.5.

Then the cascade. In 60,111 US nursing home residents with a hip fracture, 36.2% were dead within 180 days. Of those who had been mobile, 53.5% had died or become newly totally dependent in walking. That sits downstream of a prescribing decision.

Does deprescribing prevent falls?

Not on its own, as far as trials show. This is the most common overstatement in the field.

Five independent syntheses tested deprescribing programs for fall reduction. None found it. The trials were small, short, and mostly counted medications instead of fractures. Absence of evidence from underpowered trials is not evidence that the drugs do not cause falls.

Both halves stand. The exposure evidence is why a sedating drug needs a reason to be on the list. The trial evidence is why nobody should promise a family that fewer pills means fewer falls.

What does cut falls in care facilities: sustained exercise, and tailored multifactorial programs delivered with staff engagement (rate ratio 0.61). Exercise works only while it continues. It is a standing program, not a course.

What does deprescribing reliably do?

• It is safe as a discipline. Across 118 randomized trials and 417,412 patients 65 and over, interventions against inappropriate prescribing showed no signal of harm on adverse reactions, injurious falls, quality of life, emergency admissions, hospitalizations or mortality.
• It cuts the count by about half a medication per patient.
• People say yes when asked. In the Shed-MEDS trial, patients or surrogates accepted 63% of recommendations across 883 medications. The usual barrier is that nobody asked.
• Built right, it cuts restraint. Cochrane found organizational least-restraint programs probably reduce restraint use (relative risk 0.86). Staff education alone had an uncertain effect.

The mortality claim did not replicate. The 2024 update of the largest meta-analysis, covering 259 studies, found no significant reduction in randomized studies.

Can stopping a medication improve memory?

Depends on the drug. Keep the answers separate.

Benzodiazepines impair the formation of new memories while they are taken. That is anterograde amnesia, produced at the GABA-A receptor. It is how the drug works, the same property that makes midazolam useful for procedural sedation. Remove the drug and the ongoing impairment goes. Temazepam, triazolam, flurazepam, estazolam and quazepam are benzodiazepines even when a chart calls them sleeping pills.

How fully memory recovers after years of use is uncertain. Measured gains in older adults were real, described by researchers as subtle, and appeared at six to twelve months.

Other drugs impair thinking by other routes. Gabapentinoids cause sedation and psychomotor slowing, not amnesia. Anticholinergics, including several older antidepressants, work by muscarinic blockade. A resident on temazepam, amitriptyline and gabapentin carries three impairment mechanisms at once.

What nobody can promise: that cutting medications in general improves memory. The trials do not show it.

Who is DWARAA for?

A prescriber, an owner, a daughter and a nursing assistant look at the same list and need four different things.

Prescribing clinicians inherit the list at a fifteen-minute appointment without the three prescribers who built it. DWARAA covers the review read in date order, prescribing cascades, the criteria sets (Beers, STOPP/START version 3, STOPPFrail) and tapering. Beers is a prompt, not a prohibition, meant to support shared decision-making rather than replace it. No taper schedule suits everyone; the FDA and CDC both say so. A reduction that has to be reversed is information, provided restarting was a stated option from the start.

Facility ownership meets medication burden as an operational problem first: agitation on the night shift, the incident log, the family meeting, staff turnover, a quality measure. DWARAA sells nothing and publishes no savings claims. Adoption takes a policy, named owners, prescriber engagement, and review on a schedule and on triggers. Training alone has not been shown to work. Training embedded in a policy change has.

Families are allowed to ask why a parent is on eleven medications, what each is for, and whether anyone has read the whole list. You see a year where a shift sees a day. Confusion that arrived over days, or comes and goes through the day, is worth raising fast. That pattern suggests something reversible: a new drug, an infection, constipation, dehydration, pain she cannot report.

Facility staff see the change first. Notice timing. "She has been sleepier since about the third week of March" is clinical information. "She has not been herself" leaves the detective work to someone else, and usually nobody does it. If a change followed a medication change, say both facts in one sentence to the person who can act. Nothing here asks staff to question a prescription or withhold a dose.

Who writes DWARAA?

Clinical content is written and reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, founder and medical director of DWARAA. His biography. Its sister division CareGuard reviews the same buildings from the other end: conditions, not prescriptions.

How do I contact DWARAA?

DWARAA, a division of Sevadar Foundation Inc. 4477 Woodson Rd, Suite 203 St. Louis, MO 63134 Call (314) 250-5100

Say which of the four you are and what you are trying to work out. DWARAA discusses the framework and its adoption. It cannot advise on one person's medication. Send no medication lists or resident details by web form or email. For a specific drug, ask the prescriber or pharmacist who knows the whole list.

Frequently asked questions

Is deprescribing the same as a taper schedule?

No. A taper is one clinical tool a prescriber may use. Deprescribing is the whole review, and DWARAA publishes no taper schedules.

Are Z-drugs safer than benzodiazepines?

Not by much. They act largely on the same receptor, and their hip fracture risk is no lower.

Can a medication that was stopped be restarted?

Yes, and that should be stated as an option from the start. A reduction that has to be reversed shows the drug was doing something, which could not be known in advance.

Is there a 2026 Beers Criteria?

No. Anything labeled "the 2026 AGS Beers Criteria" is not an American Geriatrics Society publication. The current edition is the 2023 update, published in the Journal of the American Geriatrics Society.